Trial Profile

An Open Label Biomarker Pilot Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase 0

Latest Information Update: 30 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Denosumab (Primary)
Indications Early breast cancer; HER2 negative breast cancer; Triple negative breast cancer
Focus Biomarker; Therapeutic Use
Acronyms D-BIOMARK

12 May 2025 Results assessing denosumab's impact on breast tumor cell proliferation, apoptosis, and its potential to influence the tumor immune microenvironment published in the Breast Cancer Research
09 Dec 2023 Results(n=58) of subgroup analysis presented at the 46th Annual San Antonio Breast Cancer Symposium.
24 Oct 2023 Primary endpoint has not been met. (Antiproliferative and/or pro-apoptotic activity of denosumab) ,according to Results presented at the 48th European Society for Medical Oncology Congress

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com